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Abstract
Nicastrin (NCSTN) is a transmembrane glycoprotein that is part of the
gamma-secretase complex. Gamma-secretase is a protease complex that
cleaves type-I single-pass transmembrane proteins. There are many
potential substrates for this complex, including NOTCH receptors and
amyloid precursor proteins (APP). There are a number of commercial
antibodies to nicastrin, but they do not agree on expected peptide size. We
confirmed the specificity of a C-terminal binding rabbit anti-human antibody
from Sigma-Aldrich (#N1660) using wildtype HEK293 cells and HEK293
cells deleted for nicastrin. The wildtype cells showed a prominent band at
approximately 110 kDa. We confirmed this larger than expected sized was
due to glycosylation by treating the lysate with peptide-N-glycosidase F
(PNGase F), which reduced the band to less than 75 kDa. These data
suggest that this polyclonal is specific for nicastrin and can detect
endogenous levels of protein.
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REVISED Amendments from Version 1
      
The major change in this revision is the addition of a blot showing
the antibody works with murine-derived protein as well. Otherwise
we have revised the manuscript to alter some language and
include important references suggested by the reviewers. There
is also new underlying data for this figure that has been uploaded
to FigShare.
Any further responses from the reviewers can be found at the
end of the article

Introduction

The γ-secretase complex is a multi-subunit, intramembrane protease (reviewed1). It cleaves type-I single-pass transmembrane
proteins within their transmembrane domain. This can lead
to the release of an intracellular and an extracellular domain
that may perform other functions. Examples include the cleavage of amyloid precursor protein (APP) to produce amyloid beta
and the cleavage of activated NOTCH receptors to release their
intracellular domain for translocation to the nucleus2.
Gamma-secretase is composed of several proteins, including a presenilin protease (PSEN1 or PSEN2), the presenilin enhancer gamma-secretase subunit (PEN2), an anterior
pharynx-defective 1 protein (APH1A or APH1B), and nicastrin
(NCSTN)3. Nicastrin acquires extensive N-linked glycosylation
during its maturation4,5, though the glycosylation may not be
required for typical cleavage activity6. The three-dimensional
structure of human gamma-secretase shows that the heavily glycosylated ectodomain of nicastrin forms a horseshoe-like clamp
on the extracellular portion of the complex7,8. It is thought that
NCSTN may help control substrate selectivity9. Understanding
the role of nicastrin in gamma-secretase has been challenging.

Gamma-secretase can cleave many substrates without nicastrin, though nicastrin does help to exclude some substrates via
steric hindrance10–12. There are multiple commercial antibodies for NCSTN available, but they do not agree on the expected
product size. We validated one commercial polyclonal antibody (#N1660; Sigma-Aldrich) using HEK293 wildtype and
nicastrin knockout cells.

Methods
Antibody details
We used a commercially available rabbit anti-human IgG
polyclonal antibody that targets human nicastrin (#N1660;
Sigma-Aldrich, St. Louis, MO, USA; RRID:AB_477259) which
is has performed well in some previous publications13,14. The
antibody was raised against Uniprot nicastrin peptide Q92542
(709 amino acid total size). The polyclonal was generated by
challenging rabbits with a synthetic peptide corresponding
to the C-terminal cytoplasmic domain of nicastrin (peptides
693-709) fused with keyhole limpet hemocyanin as an adjuvant.
The technical documentation claims this subsequence is identical to the matching region of nicastrin in mouse. However, aligning Q92542 to the primary mouse nicastrin peptide sequence
(NP_067620.3) with Clustal Omega15,16 actually shows 1 mismatch (94.1% identity; Figure 1). It’s unclear if this discrepancy is due to changes to either the human or mouse peptide
sequence for the most common isoform over time as the
references have been updated.
We used a mouse anti-human beta actin monoclonal antibody (#AB6276; Abcam, Cambridge, MA, USA; RRID:
AB_2223210) as a loading control. The details of all primary
and secondary antibodies are summarized in Table 1.

Figure 1. Human / mouse nicastrin alignment. Shown is a partial alignment between human and mouse nicastrin. The highlighted area
represents the peptides use for generation of the polyclonal antibody. Asterisks represent a matching amino acid between the two sequences,
and spaces are mismatches.

Table 1. Details of the primary and secondary antibodies.
Antibody (Ab)

Manufacturer

Catalog
Number

RRID

Lot number

Ab
Ab type
species

Anti-Nicastrin

Sigma

N1660

AB_477259

076M4843V

rabbit

polyclonal

Anti-beta Actin (AC-15) abcam

ab6276

AB_2223210

GR181659-16

mouse

monoclonal

Goat Anti-Rabbit IgG
(H&L)- HRPO

Leinco Technologies

R115

AB_2810875

0117L320

goat

polyclonal

Goat Anti-Mouse IgG
(H&L)- HRPO

Jackson
ImmunoResearch

115-035-003

AB_10015289 129457

goat

polyclonal
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Cell lines and culture
We purchased the Human Embryonic Kidney cell line
(HEK293) from the ATCC (CRL-1573). We cultured all cells
at 37°C and 5% CO2. For culture media, we used Dulbecco’s
Modified Eagle’s Media (DMEM; Gibco, Thermo-Fisher
Scientific, #11965-084) supplemented with 5% Fetal Bovine
Serum (FBS; Gibco, Thermo-Fisher Scientific, #26140-079), 1%
HEPES (Corning, #25-060-CI), 100 U/mL penicillin / streptomycin (Gibco, Thermo-Fisher Scientific, #15140-122), and 2 mM
glutamine (Corning, #25-005-CI).
HEK293 NCSTN knockout line
We used a HEK293 NCSTN knockout line we had previously
generated using CRISPR/Cas9 genome-editing17. Briefly, we
synthesized our single-guide RNA as an IDT gBlock and cloned
it into the pCR-Blunt TOPO vector. We co-transfected the
single-guide RNA vector along with humanized Cas9 (RRID:
Addgene_43861) into HEK293 cells, plated to single colonies,
and screened for deleted clones by sequencing (Sequence Read
Archive project PRJNA268374) and RT-qPCR (Data available
from figshare, see source data18). Full methodology for RT-qPCR
is provided in the supplementary material of Cao et al.17
Cell line protein extraction
Reagent details can be found in Table 2 and Table 3. We harvested
cells at ≥90% confluence and pelleted them by centrifugation
at 4°C and 400 ×g for 5 minutes. We washed the cell pellet
three times in 10 mL of cold phosphate buffered saline (PBS).

We then added 300 µL of cold lysis buffer (50 mM Tris-HCl
pH 8.0, 2 mM EDTA, 150 mM NaCl, 1.0% NP-40, and 1.5%
protease inhibitor cocktail) and lysed the cells with constant agitation for 30 minutes at 4°C. We removed insoluble
debris by centrifugation for 15 minutes at 4°C and 10,400 ×g.
We determined the concentration of the cleared lysates using
a Pierce BCA assay kit (#23227). We stored the lysates in
aliquots at -80°C until further use.

Mouse liver protein extraction
We received a snap-frozen mouse liver (2 month-old C57BL/6
mouse) from the Alfred Kim lab, which had been obtained
according to their approved IACUC protocol. We minced the
liver into pieces and homogenized in ice-cold lysis buffer
(5 mM Tris-HCl pH 8.0, 250 mM sucrose, 5 mM EDTA, 1.5%
protease inhibitor cocktail) using a Wheaton tissue grinder. We
then passed the solution through a QIAshredder spin-column
(Qiagen #79656) to facilitate more complete lysis. We spun
cellular debris out of solution by a 5 minute spin at 5,000 xg.
We then precipitated membrane-enriched fragments by spinning
for 5 minutes at 11,000 xg (4°C), then spinning the supernatant for an additional 1 hour at 4°C and 11,000 xg. We then
extracted proteins from the membrane pellet by resuspending
in buffer containing 2% (v/v) Triton X-100 and incubating
on ice for 30 minutes. Any remaining unlysed material was
pelleted with a 1 hour, 4°C, 11,000 xg spin. We determined the
protein concentration of the lysate using the Pierce BCA assay
kit. We stored lysates in aliquots at -80°C until blotting.

Table 2. Details of Cell lysis reagents.
Reagent

Manufacturer

Catalog Number

1M Tris–HCl pH 8

Corning

46-031-CM

0.5M EDTA pH8

Corning

46-034-Cl

5M NaCl

Sigma

S5150

Surfact-Amps NP-40
Detergent Solution

Thermo Scientific 85124

Protease Inhibitor Cocktail

Sigma

P8340

Sucrose

Sigma

S1888

Triton X-100

Sigma

T8787

Table 3. Details of SDS-PAGE / Immunoblotting reagents.
Protocol Steps

Reagents

Manufacturer

Catalog Number

Protein concentration
measurement

Pierce BCA Protein assay kit

Thermo Scientific

23227

Cell lysate preparation

2x Laemmli sample buffer β-mercaptoethanol

Biorad Sigma

161-0737 M3148

Electrophoresis

7.5% Mini-PROTEAN TGX gel, 10wl, 30 µl 10X
Tris/Glycine/SDS Buffer

Biorad
Biorad

4561023
161-0732

Immunoblotting

Immobilon-P PVDF Membrane (0.45 µm)
2-Propanol
10X Tris/Glycine Buffer
10X TBST

Millipore
Sigma
Biorad
EZ BioResearch

IPVH08100
190764
161-0734
S-1012

Chemiluminescence reaction SuperSignal West Pico Chemiluminescent Substrate Thermo Scientific

34080
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Enzymatic deglycosylation
We used peptide-N-glycosidase F (PNGase F; #P0704S; New
England Biolabs, Ipswich, MA, USA) to remove N-linked
sugars. We denatured about 50 µg of protein in glycoprotein
denaturing buffer (included with NEB kit; 0.5% SDS, 40 mM
DTT) at 100°C for 10 minutes, and then incubated the lysate with
PNGase F for 3 hours at 37°C, according to the manufacturer’s
instructions. We treated a control in parallel under the same
conditions, but omitted the PNGase F enzyme.
Immunoblotting
We denatured the protein lysate by boiling for 5 minutes in
Laemmli sample buffer (5% β-mercaptoethanol). We resolved
the proteins on precast 7.5% polyacrylamide gels (Mini-protean
TGX; Bio-Rad, Hercules, CA, USA) after loading approximately 20 µg of lysate. We used the Precision Plus Dual-Color
Standard as a molecular weight marker (Bio-Rad, Hercules,
CA). We prepared PVDF membranes (0.45 µm) by incubating
2 minutes in 100% isopropanol, washing in Milli-Q water for
2 minutes, and equilibrating in transfer buffer for 10 minutes.
We transferred separated proteins to the PVDF membrane in
transfer buffer without methanol at 200 mA for 2 hours. We
blocked the membrane by incubating in blocking buffer (TBST
with 5% skim milk powder) for 1 hour at room temperature
with gentle rocking. We probed the membrane using primary
antibodies to nicastrin (1/1000) and beta actin (1/5000)
diluted in blocking buffer overnight at 4°C with gentle rocking. We removed excess unbound antibody by rinsing the
membranes 5 times for 10 minutes each in TBST buffer. The
anti-mouse and anti-rabbit secondary antibodies were both conjugated to horseradish peroxidase (HRP). We incubated the
membranes with secondary antibody (1/7000) in blocking
buffer for 1.5 hours at room temperature, followed by washing
5 times for 10 minutes each in TBST. We used the Supersignal
West Pico Chemiluminescent Substrate reagent (ThermoFisher,
Waltham, MA) to detect secondary antibodies.

Results
The nicastrin polyclonal binds to endogenous nicastrin in
HEK293 extracts
We collected protein lysates from wildtype HEK293 cells
and HEK293 NCSTN knockouts. The manufacturer provided
example blots were derived from HEK293 cells, but used an
overexpression construct. In wildtype HEK293 cell lysates,
a single, strong band at ~110 kDa can be seen on the blot,
and this band is missing in the nicastrin knockout line lysates
(Figure 2A, underlying data19,20). The loading controls for
the wildtype replicates and knockout replicates all show the
expected band for actin (Figure 2B, underlying data19,20), supporting that the loss of the nicastrin band is specific to the
knockout and not a loading error. It is worth noting that despite
a low background, the nicastrin blots showed an approximately 25 kDa band in both wildtype and knockout lysates. We
searched the protein sequence used to develop the antibody
(KADVLFIAPREPGAVSY) with protein blast using the Homo
sapiens non-redundant peptide database automatically adjusted
for short queries, but only matches to nicastrin had a reasonable e-value (2×10-9 to 7×10-11). It is therefore unclear if this
band is from a non-specific contaminant in the antibody, a

Figure 2. Immunoblot of endogenous nicastrin. A. The NCSTN
antibody binds to endogenous levels of protein in wildtype (WT)
HEK293 cells with a band at ~110 kDa. The band is absent in NCSTN
knockout (KO) cells. Both replicates show an unidentified band at
25 kDa. B. The actin antibody shows the expected ~42 kDa band in
both replicates of wildtype and knockout cells. Abbreviations: rep.,
replicate.

similar peptide that is poorly annotated in the non-redundant
protein database, or a nicastrin degradation product.

The larger than expected band size for nicastrin is due to
glycosylation
The nicastrin antibody documentation lists the expected fragment size as approximately 110 kDa, and this band size was confirmed on our blots. However, calculating the fragment size of
human nicastrin protein sequence Q92542 using Expasy tools21
gives an estimated 78.4 kDa size for the nascent fragment and
a reduced 75.2 kDa size after cleavage of the signal peptide.
We hypothesized this discrepancy might be due to glycosylation.
We tested this hypothesis by first treating the lysates PNGase F,
which will release asparagine-linked oligosaccharides. This
reduced the molecular weight of the nicastrin band to less than
75 kDa (Figure 3A, underlying data22,23) without affecting the
actin band (Figure 3B underlying data22,23). This phenomenon
of a smaller than expected nicastrin band has been observed
previously6,24. It is possible that a longer signal sequence
than expected is cleaved from the nascent peptide. Given that
detailed information is available for the signal cleavage of
nicastrin9, a more likely explanation might be that the charge
profile of the polypeptide affects its migration.

The antibody binds to endogenous mouse nicastrin
As noted above, there were mismatches between the sequence
used to generate the antibody and the mouse sequence for
nicastrin. It was possible that this mismatch was enough to
reduce the effectiveness of this antibody in mouse extracts. We
extracted protein from frozen mouse liver to test this possibility.
We were able to confirm the presence of a band of the expected
size in the mouse extracts (Figure 4, underlying data25). The
same small, non-specific band was present in these blots as well.
Page 5 of 14
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protein. It is unclear how well the antibody would work for
cell staining due to the non-specific 25 kDa band we observed
on nicastrin blots. Based on these data obtained with the
protocols described above, we can confirm the utility of this
nicastrin antibody for immunoblotting.

Data availability
Source data
Home sapiens HEK293 NCSTN knockout by Cas9, Accession
number: PRJNA268374
Figshare: HEK293 nicastrin knockout RT-qPCR. https://doi.
org/10.6084/m9.figshare.7578539.v118
Figure 3. Nicastrin immunoblot with PNGase F treatment. A. In
lysates untreated with PNGase F (-), the expected ~110 kDa band
is present. With PNGase F treatment (+), the band regresses to less
than 75 kDa. B. In both PNGase treated and untreated lysates, the
beta actin band is unchanged.

This project contains the following source data:
• k nockout_rtqpcr.csv (Raw Ct values of RT-qPCR
confirming the knockout (CRISPR-Cas9 mediated) of
nicastrin in HEK293 cells.)
Data are available under the terms of the Creative Commons
Attribution 4.0 International license (CC-BY 4.0).

Underlying data
Figshare: NCSTN antibody validation - actin antibody in HEK293
knockout line. https://doi.org/10.6084/m9.figshare.8952968.v119
This project contains the following underlying data:
• A
 ntibodyValidation_NCSTN_KO_actin_Ab.svg
(TIF
image of actin antibody blot stored in a scaleable vector
graphic file)
Figshare: NCSTN antibody validation - NCSTN antibody in
HEK293 knockout line. https://doi.org/10.6084/m9.figshare.
8952953.v120
This project contains the following underlying data:

Figure 4. Immunoblot of murine nicastrin. Blot showing the results
for 35 µg (1) or 25 µg (2) of mouse membrane protein lysate. The
expected ~110 kDa band for mature nicastrin is present, as is the
non-specific band present in most blots at < 25 kDa. These data
suggest the antibody works as well for murine nicastrin as it does
for human nicastrin.

• A
 ntibodyValidation_NCSTN_KO_NCSTN_Ab.svg (TIF
image of NCSTN antibody blot stored in a scaleable
vector graphic file)
Figshare: NCSTN antibody validation - actin antibody in HEK293
knockout line after PNGase treatment. https://doi.org/10.6084/
m9.figshare.8952983.v122
This project contains the following underlying data:

Conclusion
We tested by immunoblot an anti-nicastrin antibody using
HEK293 cell lysates and mouse liver extracts. Our results show
that the antibody is sensitive enough to detect endogenous
protein with reasonable specificity. It is able to bind to both
glycosylated nicastrin and nicastrin without sugar linkages.
The antibody functions for both endogenous human and mouse

• A
 ntibodyValidation_NCSTN_PNGase_actin_Ab.svg (TIF
image of actin antibody blot stored in a scaleable vector
graphic file)
Figshare: NCSTN antibody validation - NCSTN antibody in
HEK293 knockout line after PNGase treatment. https://doi.
org/10.6084/m9.figshare.8952977.v123
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This project contains the following underlying data:
• A
 ntibodyValidation_NCSTN_PNGase_NCSTN_Ab.svg
(TIF image of NCSTN antibody blot stored in a scaleable
vector graphic file)
Figshare: NCSTN antibody validation - NCSTN antibody with
murine liver protein. http://www.doi.org/10.6084/m9.figshare.
11541864.v125
This project contains the following underlying data:
• S
 uppFig5_MouseNCSTN.svg (TIF image of NCSTN
antibody blot stored in a scaleable vector graphic file)

Data are available under the terms of the Creative Commons
Zero “No rights reserved” data waiver (CC0 1.0 Public domain
dedication).
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Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Molecular biology, Biochemistry, Neuropathology
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.
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Satoru Funamoto
Laboratory of Neuropathology, Graduate School of Life and Medical Sciences, Doshisha University,
Kyoto, Japan
This reviewer thinks that this manuscript is sufficient for the F1000Research.
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Are sufficient details of materials, methods and analysis provided to allow replication by others?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Neuropathology and biochemistry
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.
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VIBKU Leuven Center for Brain & Disease Research, Leuven, Belgium
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The authors validated a commercially available rabbit polyclonal anti-Nicastrin antibody from
Sigma-Aldrich (#N1660) in immunoblot analysis, using as inputs total lysates from wildtype and Nicastrin
knockout HEK293 cell lines. The N1660 antibody, generated against a synthetic peptide corresponding to
the C-terminal cytoplasmic part of human Nicastrin (693-709), identified a band at ~110 kDa only in the
wild type lysate and another band at ~ 25 kDa in both wildtype and knockout lysates. The data does not
clarify whether the low-molecular weight signal is a non-specific band or a nicastrin-derived peptide.
Treatment with PNGnase F to remove all N-linked oligosaccharide chains, reduced the molecular weight
of the nicastrin band to less than 75 kDa, without affecting the loading control actin band. The observed
shift in molecular weight is supported by previous observations (Herreman A. et al., 20031) and the
authors should acknowledge this study.
Other Points:
The authors should test the N1660 antibody against mouse Nicastrin.
“It is thought that NCSTN may help control substrate selectivity.” The ‘substrate receptor” model
(Shah et al, 20052) has been challenged by independent studies (ChávezGutiérrez et al, 20083;
Zhao et al, 20104), and it is not supported by available high resolution structural data for the
gamma secretase complex (Bai et al, 20155). More recent studies indicate that the ectodomain of
NCT has both passive and active roles in gamma secretase-mediated proteolysis. On one hand, it
restricts the access of substrates presenting large ectodomains by steric hindrance (Bolduc et al,
20166). On the other, it has an active role in the regulation of the sequential proteolysis of APP and
response to gamma secretase modulators (GSMs); thus, nicastrin modulates Aβ length.
“This phenomenon of a smaller than expected nicastrin band has been observed previously. It is
possible that a longer signal sequence than expected is cleaved from the nascent peptide, or the
charge profile of the polypeptide affects its migration.” Shah et al., 20052 provides information
about the precise signal peptide sequence cleaved from the nascent NCT polypeptide.
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Is the work clearly and accurately presented and does it cite the current literature?
Partly
Are sufficient details of materials, methods and analysis provided to allow replication by others?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Biochemistry, Intramembrane proteolysis, Alzheimer's Disease
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard, however I have significant
reservations, as outlined above.
Author Response 08 Jan 2020

Elisha Roberson, Washington University, St. Louis, USA
Reviewer question 1: Treatment with PNGnase F to remove all N-linked oligosaccharide chains,
reduced the molecular weight of the nicastrin band to less than 75 kDa, without affecting the
loading control actin band. The observed shift in molecular weight is supported by previous
observations (Herreman A. et al., 2003) and the authors should acknowledge this study.
Response: This is a valid point, and have cited the appropriate study. Thanks for the
suggestion.
Reviewer question 2: The authors should test the N1660 antibody against mouse Nicastrin.
Response: As requested we used murine protein to test the antibody. This data has been
added as Figure 4, and the expected band size was observed, along with the non-specific
small molecular weight band that show up in the HEK293 blots.
Reviewer question 3: "It is thought that NCSTN may help control substrate selectivity.” The
‘substrate receptor” model (Shah et al, 2005) has been challenged by independent studies
(ChávezGutiérrez et al, 2008; Zhao et al, 2010), and it is not supported by available high resolution
structural data for the gamma secretase complex (Bai et al, 2015). More recent studies indicate
that the ectodomain of NCT has both passive and active roles in gamma secretase-mediated
proteolysis. On one hand, it restricts the access of substrates presenting large ectodomains by
steric hindrance (Bolduc et al, 2016). On the other, it has an active role in the regulation of the
sequential proteolysis of APP and response to gamma secretase modulators (GSMs); thus,
nicastrin modulates Aβ length.
Response: These are all excellent points. It is, of course, not possible to exhaustively
discuss all the possibilities for nicastrin function in gamma-secretase in the introduction,
as that is more suitable to a full literature review. However, these are points worth at least
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discuss all the possibilities for nicastrin function in gamma-secretase in the introduction,
as that is more suitable to a full literature review. However, these are points worth at least
mentioning, and good references to support the paper. We have revised the paper to point
to some of these different evidence sets regarding nicastrin function and have added the
suggested references.
Reviewer question 4: “This phenomenon of a smaller than expected nicastrin band has been
observed previously. It is possible that a longer signal sequence than expected is cleaved from the
nascent peptide, or the charge profile of the polypeptide affects its migration.” Shah et al., 2005
provides information about the precise signal peptide sequence cleaved from the nascent NCT
polypeptide.
Response: Given the work from Shah determining the signal peptide sequence, we have
revised this section to point out this information (referencing the paper). We have also
reworded to suggest that perhaps the disparity is more likely to be due to conformation /
charge profile than additional signal peptide sequence cleavage.
Competing Interests: I have no competing interests to report.
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Satoru Funamoto
Laboratory of Neuropathology, Graduate School of Life and Medical Sciences, Doshisha University,
Kyoto, Japan
It is very important to validate commercial antibodies. However this reviewer thinks it would help to
enhance the value of this manuscript if authors consider the below:
1. Sigma’s anti-Nicastrin antibody has been already a golden standard for Nicastrin detection. It is not
clear how other commercial antibodies do not agree on size. It is very important to show bands
detected with several commercial anti-Nicastrin antibodies. This could be very informative.
2. It is already published that PNGase and Endo H treatments altered migration distance of Nicastrin
in gels1.
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Is the work clearly and accurately presented and does it cite the current literature?
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Are sufficient details of materials, methods and analysis provided to allow replication by others?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Neuropathology and biochemistry
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard, however I have significant
reservations, as outlined above.
Author Response 08 Jan 2020

Elisha Roberson, Washington University, St. Louis, USA
Reviewer question 1: Sigma’s anti-Nicastrin antibody has been already a golden standard for
Nicastrin detection. It is not clear how other commercial antibodies do not agree on size. It is very
important to show bands detected with several commercial anti-Nicastrin antibodies. This could be
very informative.
Response: We agree that a comprehensive screening of multiple antibodies would be
fruitful. For this experiment we focused on validating a commonly used antibody to
ensure that it was suitable for our future experimental designs. We are considering this
project in the future, given that we can generate the necessary funds to purchase the
requisite antibodies.

Reviewer question 2: It is already published that PNGase and Endo H treatments altered migration
distance of Nicastrin in gels.
Response: It has been previously published in your suggested reference from 2003. We
are able to confirm that this effect still persists, and that >15 years later the antibody
specificity is still acceptable. We appreciate the suggestion for this reference and have
appropriately cited it in the revised version.
Competing Interests: We declare no competing interests.
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Author Response 31 Jul 2019

Elisha Roberson, Washington University, St. Louis, USA
Thanks Anita! That's very helpful.
Eli
Competing Interests: Author

Reader Comment 30 Jul 2019

Anita Bandrowski, RRID, San Diegoe, USA
I have registered your antibody:
"Goat Anti-Rabbit IgG (H&L)- HRPO
Leinco Technologies
R115N/A
0117L320
goat
polyclonal"
and obtained the following RRID:AB_2810875
Competing Interests: I run the the RRID project.
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